论文部分内容阅读
目的:了解临床实践中心房颤动(房颤)患者抗栓治疗的现状及分析。方法:调查2003年(225例) -2004年(280例)年间有血栓栓塞高危因素的房颤患者接受抗栓治疗的情况。结果:发现2年间高危因素有明显增加(由平均1．4个增加到1．8个),但接受抗栓治疗均以阿司匹林为主(64．8％与72．5％),服用华法林的比例很低(4．0％与6．25％),且剂量均偏低。结论:临床实践中房颤接受抗栓治疗达到标准的比例很低,接受阿司匹林治疗者较多,但剂量偏少,接受华法林治疗者很少,房颤的抗栓治疗尚需进一步规范。
Objective: To understand the status and analysis of antithrombotic therapy in patients with atrial fibrillation (AF) in clinical practice. METHODS: We investigated the use of antithrombotic therapy in patients with atrial fibrillation who were at high risk of thromboembolism in 2003 (225 cases) - 2004 (280 cases). Results: The risk factors of 2 years were significantly increased (from an average of 1.4 to 1.8), but aspirin (64.8% vs 72.5%) was the antithrombotic therapy. The proportion of forest is very low (4.0% and 6.25%), and the dose is low. CONCLUSIONS: In clinical practice, the proportion of patients receiving atrial fibrillation to antithrombotic therapy is very low. More patients receive aspirin, but the dose is lower, fewer patients receive warfarin, and antithrombotic therapy of atrial fibrillation needs to be further regulated.